Načítá se...
Osimertinib (AZD9291) increases radio-sensitivity in EGFR T790M non-small cell lung cancer
Osimertinib (AZD9291) is a third generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor that has demonstrated significant clinical benefits in patients with EGFR-sensitizing mutations or the T790M mutation. However, the potential therapeutic effect of osimertinib combined with...
Uloženo v:
| Vydáno v: | Oncol Rep |
|---|---|
| Hlavní autoři: | , , , , , , , , , , |
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
D.A. Spandidos
2019
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6278463/ https://ncbi.nlm.nih.gov/pubmed/30365094 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3892/or.2018.6803 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|